Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.

ABSTRACT: Acute myeloid leukaemia is prevalent in older patients that are often ineligible for intensive chemotherapy and treatment options remain limited with azacitidine being at the forefront. Azacitidine has been used in the clinic for decades, however, we still lack a complete understanding of the mechanisms by which the drug exerts its anti-tumour effect. To gain insight into the mechanism of action, we defined the mutational profile of sequential samples of patients treated with azacitidine. We did not identify any mutations that could predict response and observed lack of a uniform pattern of clonal evolution. Focusing on responders, at remission, we observed three types of response: (1) an almost complete elimination of mutations (33%), (2) no change (17%), and (3) change with no discernibl

SUBMITTER: Symeonidou V 

PROVIDER: S-EPMC9421974 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature